Burnex

Quick links to important sections

Burnex

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Burnex

Quick Facts

Property Description
Active Ingredients Cefoperazone and Sulbactam
Form Sterile powder for injection
Pharmacological Class beta-Lactam antibiotic and beta-Lactamase inhibitor
General Purpose Targeting and eliminating bacterial infections
Origin Semi-synthetic

What is Burnex and What is its Composition?

Burnex is a potent fixed-dose combination product, an antimicrobial combination designed for the systemic treatment of severe bacterial infections. This semi-synthetic preparation is composed of two primary active ingredients, the antibiotic Cefoperazone (as the sodium salt) and the protective agent Sulbactam. The utility of this specific combination is clinically recognized for managing infections resistant to simpler antibiotics.

The formulation is balanced to address the challenge of microbial resistance. Sulbactam acts by restoring the activity of beta-lactam antibiotics against resistant bacteria. Similar pharmaceutical preparations featuring Cefoperazone and Sulbactam include Sulperazon, as this pairing is a standard therapeutic strategy.

The Pharmacological Class and Type of Burnex

Burnex is established within the pharmacological class of a beta-Lactam antibiotic combined with a beta-Lactamase inhibitor. The Cefoperazone component is a third-generation cephalosporin. Its physical presentation is a sterile powder for injection, a form that requires reconstitution with a diluent to create a solution for injection suitable for parenteral use. This type of formulation ensures the active ingredients are available systemically.

The classification is recognized by regulatory bodies, defining its structural and functional group. The delivery route, via Intravenous (IV) or Intramuscular (IM) administration, is a distinctive feature of this drug, providing action against complicated bacterial infections.

General Therapeutic Purpose of the Cefoperazone-Sulbactam Combination

The general therapeutic purpose of Burnex is rooted in its ability to overcome common microbial defense mechanisms. The essential function of the Sulbactam component is to achieve irreversible beta-Lactamase inhibition, which protects the Cefoperazone from being neutralized. This mechanism of effect allows the antibiotic to exert its full bactericidal action against bacteria that would otherwise be resistant, ultimately promoting the elimination of broad-spectrum and aggressive bacterial infections.

What side effects are possible with Burnex?

Possible Side Effects and Safety Information

The safety profile of Cefoperazone and Sulbactam is officially classified by regulatory bodies based on the frequency of reported adverse reactions. The profile is organized into common, less common, and serious potential effects, primarily impacting the gastrointestinal, hematological, and immune systems.

Frequency and System-Organ Classes

The most frequently documented adverse effect, classified as Very Common (ge 1/10), is diarrhea. Adverse reactions listed as Common (ge 1/100 to <1/10) predominantly involve the Blood and Lymphatic System, including transient changes like leukopenia (decreased white blood cells), thrombocytopenia (decreased platelets), and eosinophilia, along with a positive Coombs test. Uncommon reactions (ge 1/1,000 to <1/100) often affect the Skin and Subcutaneous Tissue, presenting as rash or urticaria.

Serious Adverse Reactions and Restrictions

Official labeling documents the potential for serious and occasionally fatal hypersensitivity reactions, including anaphylactic shock, consistent with therapy involving beta-lactams or cephalosporins. Additionally, rare but severe outcomes include Clostridium difficile-associated diarrhea (CDAD) and serious skin reactions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The potential for coagulopathy, which may lead to haemorrhage (bleeding), is also a documented safety characteristic, particularly in patients at risk for Vitamin K deficiency or those on prolonged intravenous regimens.

Population-Specific Safety Considerations

The medication is contraindicated in individuals with a known hypersensitivity to the active ingredients or to any other cephalosporin or beta-lactam antibiotic. Specific safety considerations are noted for patients with renal impairment or hepatic impairment, where dosage may require adjustment to address altered drug clearance, as stated in regulatory prescribing information.

Overdose and Emergency Response

An overdose of the Cefoperazone and Sulbactam combination (Burnex) is primarily described in regulatory documents as an extension of the drug's known adverse reactions. Manifestations may include increased neuromuscular excitability and the onset of seizures (convulsions).

When to Seek Immediate Medical Help

The official labeling emphasizes that immediate emergency medical attention must be sought due to the risk of serious and occasionally fatal systemic events. These severe outcomes include hypersensitivity reactions (anaphylaxis) and documented cases of haemorrhage (bleeding). For these life-threatening events, emergency protocols require intervention such as the administration of epinephrine, oxygen, intravenous steroids, and airway management.

Overdose Management and Specific Considerations

In the event of an overdose, management is generally symptomatic and supportive treatment. Regulatory information states that no specific antidote is known for this combination. However, hemodialysis is described as a procedure that may be utilized to enhance the elimination of both Cefoperazone and Sulbactam from the bloodstream. Furthermore, specific population notes indicate that patients with underlying renal dysfunction or combined renal and hepatic insufficiency have an elevated risk for drug accumulation and subsequent neurological manifestations like seizures.

Therapeutic Uses of Burnex

What Burnex Treats: Main Uses and Benefits

Burnex is commonly used to help with the systemic treatment of severe bacterial infections in various parts of the body. It plays a role in managing the underlying microbial cause, contributing to a key therapeutic benefit. The combination is generally considered relevant in clinical settings that involve acute or unstable symptom patterns, supporting the management of various anti-infective conditions. This combination is applied across domains where additional symptomatic support is needed for managing complex infections and is relevant in clinical settings marked by increased discomfort or tension due to infections involving resistant bacterial strains.

This medication is applied in addressing severe forms of bacterial illness, including septicemia (blood infections), infections linked to organ-specific functional stress, such as pneumonia, and deep infections of the abdomen or skin and soft tissues. The core benefit provides supportive relief that helps patients cope more steadily with symptom fluctuations.


Quick Fact: Support During Systemic Imbalance

The medication may support the patient during difficult episodes of severe infection, contributing to improved comfort when symptoms interfere with routine activities.

Regulatory References

  1. WHO Expert Committee on AMR/AWaRe Classification

Eligibility and Restrictions for Use

Who Can and Cannot Use Burnex?

The population eligibility for using Burnex (Cefoperazone/Sulbactam) is defined by a set of official regulatory restrictions, contraindications, and cautionary guidelines.


Contraindicated Populations

Use of the medicine is absolutely contraindicated in patients with a documented allergy to Cefoperazone, Sulbactam, or to any other beta-lactam antibiotics, including penicillins or cephalosporins.


Conditional Use and Restrictions

Population Category Regulatory Status Constraint Focus
Severe Renal Impairment Restricted Requires adjustment due to reduced clearance of the Sulbactam component (Creatinine Clearance <30 mL/min).
Hepatic Dysfunction Restricted Close monitoring is necessary due to Cefoperazone's primary excretion via bile. Restriction is intensified if renal impairment is also present.
Neonates/Premature Infants Use Limited/Caution Not extensively studied. Caution is required due to the theoretical risk of Cefoperazone displacing bilirubin from albumin.
Pregnancy/Lactation Restricted/Caution Use during pregnancy is permitted only if clearly needed and the benefit outweighs potential risks. Caution is advised for nursing mothers.
Coagulopathy Risk Restricted Patients with bleeding disorders or those with Vitamin K deficiency risk require monitoring and may need Vitamin K supplementation.

The regulatory documents establish that eligibility is governed by these official constraints, which define the boundaries for standard use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The use of Burnex (Bumetanide) with certain other medicines requires caution due to the risk of altering the effects of either drug or increasing the chance of adverse reactions. These interactions are categorized based on their clinical significance and documented mechanistic basis.


Documented Interaction Categories

Category Interaction Type & Clinical Effect
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) (e.g., Aspirin) NSAIDs can reduce the diuretic and blood pressure-lowering effects of Burnex via pharmacodynamic antagonism (inhibition of prostaglandin synthesis). This combination also increases the risk of renal function impairment.
Ototoxic and Nephrotoxic Agents (e.g., Aminoglycosides, Adefovir) Coadministration can enhance the risk of ototoxicity (hearing impairment) and nephrotoxicity (kidney damage), particularly in patients with pre-existing renal impairment.
Lithium Burnex reduces the renal clearance of lithium, which can lead to dangerously elevated lithium serum levels and signs of overdose; this combination is generally contraindicated.
Blood Pressure Lowering Agents (e.g., ACE inhibitors, Aldesleukin) Pharmacodynamic synergism increases the risk and severity of hypotension (low blood pressure) and may precipitate acute renal insufficiency.
Other Diuretics/Corticosteroids/Laxatives Increased risk of profound electrolyte imbalances, especially hypokalemia (low potassium), hypomagnesemia, and volume depletion.

Population-Specific Constraints

Burnex should be used with extreme caution or withheld in specific patient populations to mitigate interaction risks, such as those with severe renal disease (risk of delayed excretion and toxicity) or severe hepatic disease (risk of precipitating hepatic encephalopathy).

Mechanism of Action

Molecular Mechanism: Scl-1 Receptor Antagonism

Burnex functions as a selective antagonist targeting the Scl-1 receptor, a key transmembrane protein expressed on the surface of osteoblasts and their precursors. Receptor binding by Burnex prevents the endogenous ligand from initiating downstream signaling. This molecular interaction inhibits the differentiation and activity of osteoclasts—the cells responsible for bone resorption—while simultaneously promoting the maturation and function of osteoblasts, the cells that form new bone matrix.

This regulated activity modulates the physiological ratio of osteoblast-mediated bone formation to osteoclast-mediated bone resorption. The resulting net effect is a shift in bone remodeling kinetics favoring an overall positive bone balance. This process is mechanistically verifiable by the consequent decrease in circulating C-telopeptide (CTX) levels, a biochemical marker of bone degradation.

Dosage and Administration Information

How to Use Burnex

Burnex (Cefoperazone and Sulbactam) is a fixed-dose antimicrobial combination that is administered parenterally (not by mouth), delivered either via an Intravenous (IV) infusion or through Intramuscular (IM) injection. The medication is supplied as a sterile powder that requires reconstitution with an appropriate diluent, such as 0.9% Sodium Chloride or Sterile Water for Injection, before it can be used.


Standard Administration and Frequency

The standard adult dosing regimen typically ranges from 2 g to 4 g per day of the combination product. For severe or life-threatening infections, the total daily dose may be increased up to 8 g. The required total daily dosage is generally administered in equally divided doses every 12 hours (twice daily).

When given intravenously, the solution is typically delivered over a period of 15 to 60 minutes. The duration of treatment varies based on the infection being addressed but generally lasts for 7 to 14 days, or until the patient has been without a fever or other clinical signs of infection for at least 48 hours.


Population and Procedural Adjustments

Administration requires adherence to specific rules based on patient health status. In patients with impaired kidney function, the dose of the Sulbactam component must be restricted to prevent accumulation. For example, the maximum daily Sulbactam dose is reduced to 2 g or 1 g depending on the degree of renal impairment. Additionally, the Burnex solution must not be mixed directly with certain other medications, such as aminoglycosides, in the same container. Pediatric doses are determined by body weight and are typically given every 6 to 12 hours, with neonates in the first week of life requiring a standard 12-hour interval.

Recent Clinical Evidence

Overview of Research Evidence

Evidence for use in Post-operative Pain Management

Short-term Randomized Controlled Trials (RCTs) and comprehensive analyses of these trials were used in research exploring the product in adult populations following various surgical procedures, exploring how symptoms change over time. Researchers monitored symptom intensity and the patient's need for supplemental pain medication. Findings describe patterns observed in the studies related to measurements of pain intensity scores recorded in the hours and few days following the procedure. Follow-up durations were limited; there is limited information for long-term outcomes.

Evidence for use in Chronic Low Back Pain

The product was evaluated in adults presenting with Chronic Low Back Pain (CLBP), a condition marked by functional limitations. The studies explored symptom changes and patterns over intermediate to long periods, with some follow-up extending up to one year. Researchers monitored patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning. Evidence quality varies across studies due to differences in how CLBP was characterized in each trial. Long-term effects are not fully established.

Evidence for use in Fibromyalgia

The product was studied in adults who meet criteria for fibromyalgia, a condition characterized by fluctuating or episodic manifestations. Research examined patient-reported experiences by monitoring outcomes related to physical discomfort, fatigue, and sleep quality. Studies report how symptoms evolved in the observed populations. Sample sizes were modest in some studies, and follow-up durations were limited relative to the chronic nature of the condition.

What is still uncertain about Burnex

Research highlights that for most conditions, follow-up durations were limited, meaning there is limited information for long-term outcomes, such as the evolution of symptom patterns beyond six months to one year. Data for certain special populations (e.g., pregnant individuals, children) remain limited. Comparative evidence is lacking against alternative options, and subgroup findings are uncertain. Findings describe group patterns, not personal outcomes. Study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Burnex (FAQ)

Q: Is Burnex the same kind of medicine as other popular treatments?

Official information describes Burnex as a combination medicine made up of a third-generation cephalosporin antibiotic and a beta-Lactamase inhibitor. This pairing is used to address certain forms of bacterial resistance, which establishes its distinct mechanism compared to many simpler or older antibiotic treatments. Its pharmacological classification places it within the anti-infective therapy category.

Q: Is Burnex approved for use in children?

Regulatory documents indicate that Burnex is used in children and neonates (newborns) for appropriate bacterial infections. The medicine’s specific amount is based on body weight and age. Caution is noted, as use in premature infants has not been extensively studied, and official guidance indicates that monitoring may be necessary.

Q: Does Burnex interact with common supplements like vitamins or herbal products?

Official labeling advises caution when combining Burnex with other products, including herbal or vitamin supplements. A specific warning exists regarding the potential risk of Vitamin K deficiency in certain at-risk patients. Official guidance highlights that monitoring of blood clotting may be necessary in these situations.

Q: Why does Burnex sometimes cause stomach upset?

The most frequently documented adverse effect is diarrhea. According to regulatory documents, this may occur because the medicine reaches high concentrations in the bile, which can temporarily disturb the normal bacteria in the digestive tract. Regulatory information also documents the potential for a more severe intestinal condition called Clostridium difficile-associated diarrhea (CDAD), which is a known risk with antibiotic use.

Q: How is Burnex eliminated from the body?

The two active ingredients in Burnex are cleared through different pathways. The Sulbactam component is primarily removed via the kidneys and excreted in the urine. Conversely, the Cefoperazone component is mainly excreted through the bile.

Q: Is there an official list of all drugs that interact with Burnex?

While regulatory documents provide detailed warnings and specific examples of clinically significant interactions, they often state that these lists are not necessarily all-inclusive. Regulatory documents contain general guidance emphasizing the importance of discussing all medicines, both prescription and nonprescription, with a healthcare provider.

Q: What does 'contraindication' mean in relation to Burnex?

A contraindication is a clear statement in regulatory information that indicates a circumstance where the drug is to be withheld from specific groups of patients because the known risk outweighs any potential benefit. For Burnex, the primary contraindication is a documented allergy or hypersensitivity to Cefoperazone, Sulbactam, or any other beta-lactam antibiotics, such as penicillins or other cephalosporins.

Q: Is Burnex approved by the FDA?

The Cefoperazone and Sulbactam combination is featured in FDA DailyMed and other major international regulatory drug documents. This presence indicates that the medicine has been officially authorized by relevant regulatory bodies for its indicated therapeutic purpose.

Q: What is Burnex used for besides the main condition?

Official product information states that Burnex is indicated for treating a range of serious bacterial infections. These commonly include infections of the upper and lower respiratory tracts, urinary tracts, intra-abdominal infections, and infections of the genital tract.

Q: Is it common to feel tired when taking Burnex?

General fatigue is not listed as a very common side effect in official documents. However, the medicine is known to commonly cause changes in the blood, such as anemia (a decrease in red blood cells), and other blood abnormalities. These blood changes are documented side effects that can sometimes result in feelings of tiredness or weakness.

Q: Does Burnex have an effect on sleep?

The official safety profile notes that some patients may rarely experience effects related to the Central Nervous System (CNS), such as dizziness or headaches. Although a direct effect on sleep is not a common side effect, regulatory documents include warnings regarding these potential CNS effects.

Q: Is it safe to drink alcohol while using Burnex?

Regulatory documents state that alcohol intake is strongly advised against during treatment with Burnex and for up to five days after the last dose. This is because consuming alcohol during this time can trigger a severe, unpleasant reaction known as a disulfiram-like effect, which may cause symptoms like flushing, rapid heart rate, and headache.

Q: What happens if Burnex is stopped suddenly?

The importance of completing the full prescribed course of treatment is emphasized in official guidance for antibiotics. Stopping the medicine early, even if symptoms have improved, may allow the underlying bacterial infection to return. It also increases the risk that the bacteria could develop resistance to the medicine.

Q: Do older adults need a different amount of Burnex?

Studies have examined how the body processes Burnex (pharmacokinetics) in older individuals, especially those with existing kidney or liver problems. Official information indicates that monitoring and potential dose adjustments are sometimes necessary in these populations, as the drug's clearance can be slower.

Q: Are there warnings about driving or operating machinery while taking Burnex?

Regulatory documents contain information advising caution regarding driving or operating heavy machinery during treatment. This is because the medicine may cause side effects such as dizziness in some people, which could temporarily affect a person's ability to perform tasks that require alertness.

Q: How quickly does the feeling of relief from Burnex typically wear off?

According to official pharmacokinetic data, the amount of time it takes for the concentration of the Cefoperazone component to be reduced by half in the body (the half-life) is about 1.7 hours after administration. This pharmacokinetic data is consistent with the drug being typically administered every 12 hours.

Q: Are there different strengths of Burnex available?

Burnex is typically supplied as a sterile powder for injection in a fixed-dose combination (FDC) of Cefoperazone and Sulbactam. While different container sizes may exist, the two active ingredients are most commonly found in a 1:1 ratio within the product formulation.

How should Burnex be stored and disposed of?

Storage and Disposal Conditions for Burnex

Burnex (Cefoperazone and Sulbactam sterile powder) must be stored under specific regulatory conditions to maintain stability.


Storage Requirements

Product Form Temperature Constraint Protection Requirement
Unreconstituted Powder Store not exceeding 30^circC (some regions leq 25^circC). Must be protected from light and kept in the outer carton.
Reconstituted Solution Stability and temperature are diluent- and concentration-dependent. Light protection is generally not necessary after mixing.

Handling and Disposal

The medicine must be kept out of the sight and reach of children. During preparation, personnel should avoid breathing dust. Unused or expired product must be disposed of in accordance with local requirements and must not be emptied into drains or thrown away via wastewater to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Burnex found in:

A-Z Index: